IL6 and neoplasm: In line with our findings, Nejad et al. reported that the effect of an HPV16 E7-derived vaccine in a TC-1 tumor model was lost when IL-6 signaling was blocked with an anti-IL-6 antibody, an anti-IL-6R antibody, or both [6].